‘BNB Microstrategy’ faces imminent Nasdaq delisting as price falls below threshold
Windtree, a BNB cash company that has become biotechnology, faces the Nasdaq on August 21.
Summary
- The Nasdaq should set up Windtree on August 21, after the non-compliance of its $ 1 Course rule
- The Windtree’s equity rate has lost 97.74% in the last six months, at $ 0.11
- The cancellation would make much more difficult for Windtree to access public contracts
The pivot of biotechnology in difficulty for BNB vouchers could soon end. Tuesday August 19, regulatory deposits have shown that Windtree, sometimes called “BNB microstrategy”, is faced with an imminent delimitation on the Nasdaq on non-compliance.
According to the file with the Securities and Exchange Commission, the NASDAQ will put Windtree on August 21. Namely, Nasdaq companies must be negotiated above $ 1 per share, while Wintree, under the Wint de Ticker, is negotiated at $ 0.11.
Above all, the move could place the Windtree pivot at BNB vouchers at risk. More specifically, the NASDAQ list effectively transforms Windtree into a lever effect on BNB available on the public market. Without access to the Nasdaq, it would be more difficult for investors average to acquire Windtree’s shares.
Windtree in difficulty pivoted BNB vouchers
Windtree, a biotechnology company, announced its pivot to a BNB cash company after years of slowness. In the past six months, its stock market price has dropped 97.74% at its current level of $ 0.11.
On July 16, the company first announcement plans to buy $ 60 million of BNB tokens from Build and Build Corp., with the potential to acquire $ 140 million more. This has placed total funding of the company at $ 200 million for its BNB treasure.
A week later, on July 24, the company announced security Additional $ 520 million in funding. $ 500 would come from a line of stock in equity with undisclosed funding and an additional $ 20 million from a direct share purchase in Build and Build Corp.
Post Comment